Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WMP plus anti-obesity medication in employees
NCT03799198Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide, orlistat, lorcaserin, phentermine + topiramate and naltrexone + bupropion in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Body Weight at 12 months. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03799198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799198.